Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis (TANDEM)
Study description
The purpose of the study is to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH
Pathology
Non-alcoholic Statohepatitis NASH
Study type
Clinical trial
Status
Active
Study start date
2018
Funder Type
Industry funded study
Investigator
Dr.ssa med. Benedetta TERZIROLI BERETTA-PICCOLI
Recruitment
Recruiting
For information, please contact the Foundation